AKR1C3-IN-1 is primarily used in research focused on cancer treatment, particularly in targeting hormone-dependent cancers such as prostate and breast cancer. It functions as an inhibitor of the AKR1C3 enzyme, which plays a role in the metabolism of steroid hormones and the activation of certain carcinogens. By inhibiting this enzyme, it helps reduce the production of androgens and estrogens, which can slow the growth of hormone-sensitive tumors. Additionally, it is studied for its potential to enhance the efficacy of other anticancer therapies by modulating drug resistance mechanisms. Its application is largely confined to preclinical studies, where it aids in understanding the role of AKR1C3 in cancer progression and therapy development.